Ortoma ABOMXSTO: ORT_B

ORT_B: Revenue up, EBITDA positive, and US commercialization underway pending approvals

· Issued by Ortoma AB

Revenue grew 29% to SEK 49.1 million in 2024, with EBITDA turning positive and net loss narrowing. Commercialization advanced in the US and Japan, with regulatory approvals key for 2025 launches.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Ortoma AB on 6ix

Earlier from Ortoma

Later from Ortoma

All Ortoma news releases